← All trials
NCT04003116
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2019
- Primary completion
- Apr 24, 2022
- Completion date
- Jul 25, 2022
- First posted
- Jul 1, 2019
- Last posted
- Aug 18, 2022
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of SpainLead sponsor
- Sociedad Española de Neumología y Cirugía TorácicaCollaborator
- Government of SpainReponsible party - principal investigator
- Alcala de Henares UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.